Oxodotreotide

Oxodotreotide, or dotatate, is a ligand-linked somatostatin peptide analog also known as DOTA⁰, Tyr³]-octreotate. The peptide was invented by Jack Erion, and Ananth Srinivasan in the mid-90’s.
Oxodotreotide is closely related to the peptide, edotreotide, in that both molecules are identical, except at the C-termus, where edotreotide contains a threoninol residue, and oxodotreotide contains L-threonine.
Currently, the oxodotreotide name is only used in context with the radiopharmaceutical, lutetium (¹⁷⁷Lu) oxodotreotide, which is the international nonproprietary name (INN) assigned by WHO.
Another radiopharmaceutical with the INN, gallium (⁶⁸Ga) dotatate, is composed of the same chemical entity as lutetium (¹⁷⁷Lu) oxodotreotide, (DOTA⁰, Tyr³]-Octreotate, except that the DOTA moiety of one molecule is complexed with the radionuclide, lutetium-177, and the other is complexed with gallium-68. The gallium-68 radiolabeled peptide is used as a diagnostic PET imaging agent in patients with neuroendocrine tumors, and the lutetium-177 radiolabeled peptide is used as a therapeutic agent in patients with neuroendocrine tumors.
Both products have been developed by Advanced Accelerator Applications.
Gallium (⁶⁸Ga) dotatate is approved for use in the United States for the diagnosis of neuroendocrine tumors and is marketed under the brand name, NETSPOT^®.
Lutetium (¹⁷⁷Lu) oxodotreotide has marketing approval in the EU, and is currently under review by the FDA.
The brand name for the product is Lutathera^®.